ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1893

Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis

Angélique Lemaire1,2, Vincent Sobanski2,3,4,5, Luc Dauchet6, Eric Hachulla1,2,3,5, Sylvain Dubucquoi3,5,7, Marc Lambert1,2,3,5, Pierre-Yves Hatron1,2,8 and David Launay1,2,3,5, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, 2CHU Lille, Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), F-59000 Lille, France, Lille, France, 3Inserm, U995, F-59000 Lille, France, Lille, France, 4CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, 5Univ. Lille, U995, Lille Inflammation Research International Center (LIRIC), F-59000 Lille, France, Lille, France, 6CHU Lille, Service d’Epidémiologie, économie de la santé et prevention, F-59000 Lille, France, Lille, France, 7CHU Lille, Laboratoire d’Immunologie, F-59000 Lille, France, Lille, France, 8Univ Lille, CHU Lille, F-59000 Lille, France, Lille, France

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Antiphospholipid antibodies and systemic sclerosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Antiphospholipid antibodies (aPL) can be present in the sera of systemic sclerosis (SSc) patients. Important variations of their prevalence are observed in the literature. Their clinical associations remain largely unknown. The aim of this study was to perform a systematic review of published reports and a meta-analysis to estimate the prevalence of aPL in SSc.

Methods: A systematic review of the literature was carried out in PubMed and Embase between May 1975 and November 2015 by 3 of the authors (AL, VS and DL). We used combinations of the terms “systemic sclerosis”, “antiphospholipid antibodies”, “antiphospholipid syndrome”, “anticardiolipin antibodies”, “lupus anticoagulant”, “anti-β2GP1”, “anti-phosphatidylethanolamine”, “thrombosis”, “pulmonary embolism”, “deep vein thrombosis”, “stroke”, “myocardial infarct”, “pregnancy”. We adapted the search strategy to the specificities of each database. After screening the titles and abstracts, studies were selected after a full-length review. Inclusion criteria were: French or English-language publication, adult patients with SSc, and at least 30 patients with SSc tested for lupus anticoagulant (LA), or/and anticardiolipin (aCL) or/and anti- β2Glycoprotein 1 (anti-β2GP1) antibodies. Meta-analysis was performed using number of aPL positive (at least one of the three antibodies positive) and negative patients.

Results: 1291 references were retrieved as result of search, 79 articles were included for full text review after reading the titles and abstracts. Of these articles, 31 were assessed for eligibility. Finally, 23 studies were included in the meta-analysis, representing a total population of 2937 SSc patients. Prevalence of aPL positivity (one or more) in SSc in literature ranged from 0 to 58%. The overall pooled prevalence of aPL in SSc was 16% (95%CI [10-22]). LA was found in 0 to 16% of patients; aCL in 0 to 34% and anti-β2GpI in 0 to 50%. The prevalence of aCL was 11% (95%CI [7-15]), and prevalence of anti-β2GP1 was 9% (95%CI [3-19]). Clinical manifestations associated with aPL positivity were more frequently pulmonary arterial hypertension (PAH) or digital ulcer (DU). Six studies out of 11 found an association between aPL and PAH (aCL in 5, one or more aPL in 1). Two studies out of 8 found an association between aPL (aCL) and DU and 2 studies found a trend.

Conclusion: The prevalence of aPL in SSc was highly variable (range 0-58%). The overall pooled prevalence was 16% (95%CI [10-22]). The most frequent clinical manifestation associated with aPL positivity was PAH. AL and VS have contributed equally to this work.


Disclosure: A. Lemaire, None; V. Sobanski, None; L. Dauchet, None; E. Hachulla, None; S. Dubucquoi, None; M. Lambert, None; P. Y. Hatron, None; D. Launay, None.

To cite this abstract in AMA style:

Lemaire A, Sobanski V, Dauchet L, Hachulla E, Dubucquoi S, Lambert M, Hatron PY, Launay D. Prevalence of Antiphospholipid Antibodies in Systemic Sclerosis: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-antiphospholipid-antibodies-in-systemic-sclerosis-a-systematic-review-and-meta-analysis/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-antiphospholipid-antibodies-in-systemic-sclerosis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.